mRNA / LNP manufacturing equipment

01Overview and value chain

Markers: [EC: EU GMP Annex 1 & ICH Q13 continuous manufacturing | OECD: Bio-pharmaceuticals | Regulator: FDA (USA), EMA (EU), NMPA (China)]

mRNA / LNP manufacturing equipment is the set of mixers, skids and continuous-flow reactors that combine an aqueous mRNA stream with an ethanol-dissolved lipid blend so the four components — ionizable lipid, cholesterol, helper phospholipid and PEG-lipid — self-assemble around the mRNA into lipid nanoparticles of 80–120 nm in a few milliseconds. Two mixing geometries dominate the commercial field: impingement-jet mixing (IJM), which collides the two streams head-on inside a confined chamber at high velocity, and microfluidic staggered-herringbone mixing, which interleaves the streams in a lithographic channel. Both run continuously, scale by holding residence time constant, and feed straight into a downstream tangential-flow filtration (TFF) step that removes the ethanol and conditions the buffer before sterile fill-finish. The platform is the hardware layer behind the multi-billion-dose mRNA COVID-19 vaccines and the in-vivo delivery system for a fast-growing pipeline of gene-editing, vaccine and protein-replacement therapies.

The key directions of mRNA / LNP manufacturing equipment are:

1. Benchtop microfluidic screening (NanoAssemblr Ignite/Spark): milligram-scale staggered-herringbone mixers that let formulators sweep the flow-rate ratio, lipid composition and N/P ratio in overnight design-of-experiments runs before committing to GMP scale.
2. GMP impingement-jet skids (Knauer IJM NanoScaler/NanoProducer): the high-velocity collision geometry used to manufacture commercial mRNA vaccines, scaled by Reynolds-number matching from a benchtop NanoScaler to a multi-litre-per-minute production skid.
3. Production microfluidic platforms (NanoAssemblr Blaze/Gemini, Microfluidizer M7250): parallelised microfluidic cartridges or high-pressure interaction chambers delivering kilograms of mRNA-LNP per batch under single-use, GMP-clean flow paths.
4. Continuous-flow reactors (Corning Advanced-Flow Reactor): structured plate-and-frame continuous reactors (G1–G4) that turn LNP formation into a true continuous process aligned with ICH Q13, rather than a batch-overflowing stirred vessel.

Sectoral value chain

[lipid & mRNA preparation] ──> [continuous mixing (IJM/microfluidic/AFR)] ──> [quench & dilution]
                                                │
                                  (downstream TFF + sterile filtration)
                                                │
                                                ▼
[distribution & cold chain] <─── [fill-finish] <─────┘

Value chain levels

Cross-cutting technologies of the sector:

• Impingement-jet mixing (Impingement-Jet Mixing): high-velocity stream collision in a confined chamber, the commercial-scale mixer geometry behind mRNA COVID-19 vaccines.
• Microfluidic LNP formulation (Microfluidic LNP Formulation): lithographic-channel mixing that controls LNP size (30–270 nm) by tuning flow-rate ratio.
• Tangential-flow filtration (Tangential-Flow Filtration): the downstream ethanol-removal and buffer-exchange step that every continuous mixer feeds into.

02US

The United States is the centre of the microfluidic-mixing platform class, and the home of two of its three dominant hardware vendors: Precision NanoSystems (Vancouver, CA, a Cytiva company since 2020) and Microfluidics International (Westwood, MA). Corning (Corning, NY) adds the continuous Advanced-Flow Reactor family, and FDA’s emergency-use and full-approval pathways for mRNA vaccines are what pulled the platform from research into multi-billion-dose commercial scale.

microfluidic mixer platforms, AFR continuous reactors, FDA mRNA pathway

• Precision NanoSystems — NanoAssemblr: the staggered-herringbone platform (Ignite benchtop, Spark clinical, Blaze and Gemini commercial, Bio-Continuum continuous manufacturing) that set the de-facto LNP-process-development standard.
• Microfluidics International — Microfluidizer: high-pressure fixed-geometry interaction chambers (LM20 benchtop, M7250 production) producing uniform sub-100 nm LNP across high-shear homogenisation.
• Corning — Advanced-Flow Reactor (AFR): the G1–G4 plate-and-frame continuous reactor class, qualified for LNP and mRNA continuous manufacturing under ICH Q13.

03CN

China is the demand-side growth market for mRNA / LNP equipment: a wave of domestic mRNA vaccines (COVID-19, RSV, oncology) and the country’s cell and gene therapy pipeline are converting imported-mixer R&D lines into domestic commercial production, while NMPA’s reliance on ICH Q13 harmonises the continuous-manufacturing framework. Domestic fill-finish and bioprocessing equipment makers are pivoting toward integrated mRNA-LNP preparation lines, but the upstream microfluidic/impingement mixer hardware at production scale remains substantially imported, so the Chinese regional block is held qualitative.

domestic fill-finish pivot, ICH Q13 alignment, imported upstream mixers

• Domestic mRNA vaccine drive: Walvax/Abogen, Stemirna and CSPC mRNA programmes have built commercial-scale LNP capacity around imported NanoAssemblr and Knauer IJM skids, with domestic media, lipid and TFF supply localised around them.
• Fill-finish and bioprocessing equipment makers: domestic firms with established aseptic-filling and bioreactor lines are extending into mRNA-LNP preparation skids, but the microfluidic and impingement-jet contactor is still primarily imported at production scale.
• NMPA continuous-manufacturing alignment: NMPA adoption of ICH Q13 frames the regulatory route for continuous LNP manufacturing, paralleling FDA and EMA.

04EU

Europe anchors the impingement-jet side of the field and the CDMO offer: Knauer (Berlin, DE) builds the IJM skid family that manufactures commercial mRNA vaccines, while Evonik (Essen, DE) operates a lipid and LNP contract-development-and-manufacturing network expanded through the 2024 Wilshire acquisition, and EMA’s EU GMP Annex 1 and ICH Q13 guidance define the aseptic and continuous-manufacturing bar.

impingement-jet skids, lipid/CDMO capacity, GMP Annex 1

• Knauer — IJM NanoScaler & NanoProducer: the impingement-jet family scaled by Reynolds-number matching from benchtop NanoScaler to production NanoProducer, developed with partners such as XNApharma for RNA delivery screening.
• Evonik — Wilshire continuous processing & lipids: Evonik Health Care’s LNP CDMO, expanded through the Wilshire acquisition, pairs lipid supply with continuous processing and high-shear expertise.
• EMA GMP Annex 1 & ICH Q13: the EU aseptic-processing and continuous-manufacturing framework that qualifies LNP formation, downstream TFF and aseptic fill-finish.

05Leading companies and research institutes

06Tech stack and innovations

The stack combines the mixer contactor, the downstream TFF train and continuous-manufacturing control into one closed flow path.

1. Mixer contactors (Mixer Contactors):
   • impingement-jet chambers (Knauer IJM) colliding the two streams at high velocity, scaled by Reynolds-number matching;
   • staggered-herringbone microfluidic cartridges (Precision NanoSystems NanoAssemblr) controlling LNP size (30–270 nm) by flow-rate ratio;
   • high-pressure fixed-geometry interaction chambers (Microfluidics Microfluidizer) and plate-and-frame AFR contactors (Corning).
2. Downstream TFF train (Downstream TFF Train):
   • single-use tangential-flow cassettes that remove ethanol from the crude LNP dispersion and exchange the buffer to <1% residual organic;
   • inline dynamic-light-scattering PAT tracking particle size and polydispersity in real time.
3. Continuous-manufacturing control (Continuous-Manufacturing Control):
   • ICH Q13-aligned process control with flow-rate-ratio and total-flow feedback, enabling true continuous LNP formation rather than batch overflow.

07Value chains and production pipelines

Industrial pipeline of an mRNA-LNP manufacturing skid (ICH Q13 / GMP Annex 1)

┌───────────────────────────┐      ┌───────────────────────────┐
│ 1. Lipid & mRNA feed prep │ ───> │ 2. Continuous mixing      │
└───────────────────────────┘      └───────────────────────────┘
                                                  │
                                                  ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 4. Downstream TFF         │ <─── │ 3. Quench & dilution      │
└───────────────────────────┘      └───────────────────────────┘
              │
              ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 5. Sterile filtration     │ ───> │ 6. Fill-finish & cold chain│
└───────────────────────────┘      └───────────────────────────┘

Stage 1: Lipid and mRNA feed preparation

The four-lipid blend (ionizable lipid, cholesterol, helper phospholipid, PEG-lipid) is dissolved in ethanol, and the mRNA bulk — produced by in-vitro transcription and purified — is held in aqueous buffer as two separate feed streams.

Stage 2: Continuous mixing

The two streams meet in the mixer contactor — impingement-jet (Knauer IJM), staggered-herringbone microfluidic (NanoAssemblr), high-pressure interaction chamber (Microfluidizer) or plate-and-frame (Corning AFR) — at a tuned flow-rate ratio (typically ~1:3 organic:aqueous) and controlled total flow, self-assembling 80–120 nm lipid nanoparticles in milliseconds.

Stage 3: Quench and dilution

The crude LNP dispersion, still in ~30–50% ethanol, is immediately diluted with buffer to stabilise particle size, stop growth and bring encapsulation efficiency above 90%.

Stage 4: Downstream TFF

Single-use tangential-flow filtration cassettes remove the ethanol and exchange the buffer down to <1% residual organic, with inline DLS PAT confirming particle size and polydispersity hold.

Stage 5: Sterile filtration

The formulated LNP passes a 0.22 μm sterile filter into the fill-finish suite under EU GMP Annex 1 aseptic conditions, with container-closure integrity verified per batch.

Stage 6: Fill-finish and cold chain

The sterile LNP drug product is filled into vials, syringes or bags, lyophilised or frozen where required, and distributed at -70 °C to 2–8 °C through validated cold chain to the point of administration.